Universal access to high-quality treatment is central to the Global Plan to Stop TB. The Global Drug Facility (GDF) was launched in 2001 to help to achieve this goal, through services including the supply of aff ordable, quality-assured drugs to countries in need. We assess the scale of GDF drug supplies worldwide and fi nd that the GDF commands a substantial proportion of the market for drugs for fi rst-line and second-line treatment regimens, having supplied, for example, fi rst-line drugs for roughly 35% of cases reported worldwide in 2011. Signifi cant potential remains for GDF expansion, especially in the provision of second-line drugs, which would be aided by future increases in case detection.
展开▼